T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...
ESLA READ THE FULL ESLA RESEARCH REPORT Initiating Coverage We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with a valuation of $12.00 per share and a thesis centered on the ...
A synthetic tripeptide inspired by snake venom is opening new investigative routes into cellular signalling and structural ...
The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...
A single receptor in blood vessels can trigger either harmful inflammation or protective healing, but scientists have ...
How do blood vessels stay strong, flexible, and responsive to the body’s changing need for oxygen and nutrients? The answer lies not only in ...
A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results